301 related articles for article (PubMed ID: 27255691)
41. ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPY FOR NEOVASCULAR AGE-RELATED MACULAR DEGENERATION: Outcomes in Eyes With Poor Initial Vision.
Toth LA; Stevenson M; Chakravarthy U
Retina; 2015 Oct; 35(10):1957-63. PubMed ID: 25946692
[TBL] [Abstract][Full Text] [Related]
42. Response to aflibercept after frequent re-treatment with bevacizumab or ranibizumab in eyes with neovascular AMD.
Thorell MR; Nunes RP; Chen GW; Doshi RR; Dugar J; George MK; Kim BT; Lowrance MD; Modi D; Nahas Z; Gregori G; Yehoshua Z; Feuer W; Rosenfeld PJ
Ophthalmic Surg Lasers Imaging Retina; 2014; 45(6):526-33. PubMed ID: 25423632
[TBL] [Abstract][Full Text] [Related]
43. Inner retinal layer change in glaucoma patients receiving anti-VEGF for neovascular age related macular degeneration.
Saleh R; Karpe A; Zinkernagel MS; Munk MR
Graefes Arch Clin Exp Ophthalmol; 2017 Apr; 255(4):817-824. PubMed ID: 28127658
[TBL] [Abstract][Full Text] [Related]
44. Factors Influencing the Treatment Response of Pigment Epithelium Detachment in Age-Related Macular Degeneration.
Dirani A; Ambresin A; Marchionno L; Decugis D; Mantel I
Am J Ophthalmol; 2015 Oct; 160(4):732-8.e2. PubMed ID: 26144701
[TBL] [Abstract][Full Text] [Related]
45. Clinical utilization of anti-VEGF agents and disease monitoring in neovascular age-related macular degeneration.
Holekamp NM; Liu Y; Yeh WS; Chia Y; Kiss S; Almony A; Kowalski JW
Am J Ophthalmol; 2014 Apr; 157(4):825-833.e1. PubMed ID: 24388973
[TBL] [Abstract][Full Text] [Related]
46. Subfoveal Choroidal Thickness during Aflibercept Therapy for Neovascular Age-Related Macular Degeneration: Twelve-Month Results.
Koizumi H; Kano M; Yamamoto A; Saito M; Maruko I; Sekiryu T; Okada AA; Iida T
Ophthalmology; 2016 Mar; 123(3):617-24. PubMed ID: 26686967
[TBL] [Abstract][Full Text] [Related]
47. Determinants of visual acuity outcomes in eyes with neovascular AMD treated with anti-VEGF agents: an instrumental variable analysis of the AURA study.
Holz FG; Tadayoni R; Beatty S; Berger AR; Cereda MG; Hykin P; Staurenghi G; Wittrup-Jensen K; Nilsson J; Kim K; Sivaprasad S
Eye (Lond); 2016 Aug; 30(8):1063-71. PubMed ID: 27197868
[TBL] [Abstract][Full Text] [Related]
48. Differential Response to Anti-VEGF Regimens in Age-Related Macular Degeneration Patients with Early Persistent Retinal Fluid.
Jaffe GJ; Kaiser PK; Thompson D; Gibson A; Saroj N; Vitti R; Berliner AJ; Heier JS
Ophthalmology; 2016 Sep; 123(9):1856-64. PubMed ID: 27369111
[TBL] [Abstract][Full Text] [Related]
49. One-year outcomes of aflibercept in recurrent or persistent neovascular age-related macular degeneration.
Arcinue CA; Ma F; Barteselli G; Sharpsten L; Gomez ML; Freeman WR
Am J Ophthalmol; 2015 Mar; 159(3):426-36.e2. PubMed ID: 25461263
[TBL] [Abstract][Full Text] [Related]
50. Alternating Bi-Weekly Intravitreal Ranibizumab and Bevacizumab for Refractory Neovascular Age-Related Macular Degeneration with Pigment Epithelial Detachment
Witkin AJ; Rayess N; Garg SJ; Maguire JI; Storey P; Kaiser RS; Hsu J; Vander JF; Ho AC
Semin Ophthalmol; 2017; 32(3):309-315. PubMed ID: 26337539
[TBL] [Abstract][Full Text] [Related]
51. Topical Dorzolamide-Timolol With Intravitreous Anti-Vascular Endothelial Growth Factor for Neovascular Age-Related Macular Degeneration.
Sridhar J; Hsu J; Shahlaee A; Garg SJ; Spirn MJ; Fineman MS; Vander J
JAMA Ophthalmol; 2016 Apr; 134(4):437-43. PubMed ID: 26914218
[TBL] [Abstract][Full Text] [Related]
52. Conversion to aflibercept for chronic refractory or recurrent neovascular age-related macular degeneration.
Yonekawa Y; Andreoli C; Miller JB; Loewenstein JI; Sobrin L; Eliott D; Vavvas DG; Miller JW; Kim IK
Am J Ophthalmol; 2013 Jul; 156(1):29-35.e2. PubMed ID: 23668679
[TBL] [Abstract][Full Text] [Related]
53. CONVERSION TO AFLIBERCEPT THERAPY VERSUS CONTINUING WITH RANIBIZUMAB THERAPY FOR NEOVASCULAR AGE-RELATED MACULAR DEGENERATION DEPENDENT ON MONTHLY RANIBIZUMAB TREATMENT.
Mantel I; Gianniou C; Dirani A
Retina; 2016 Jan; 36(1):53-8. PubMed ID: 26166797
[TBL] [Abstract][Full Text] [Related]
54. Ranibizumab treatment outcomes in phakic versus pseudophakic eyes: an individual patient data analysis of 2 phase 3 trials.
Weinberg DV; Shapiro H; Ehrlich JS
Ophthalmology; 2013 Jun; 120(6):1278-82. PubMed ID: 23453513
[TBL] [Abstract][Full Text] [Related]
55. VITREOMACULAR TRACTION AFFECTS ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR TREATMENT OUTCOMES FOR EXUDATIVE AGE-RELATED MACULAR DEGENERATION.
Krishnan R; Arora R; De Salvo G; Stinghe A; Severn PS; Pal B; Goverdhan S
Retina; 2015 Sep; 35(9):1750-6. PubMed ID: 26237240
[TBL] [Abstract][Full Text] [Related]
56. Aflibercept Treatment for Neovascular Age-related Macular Degeneration and Polypoidal Choroidal Vasculopathy Refractory to Anti-vascular Endothelial Growth Factor.
Moon DRC; Lee DK; Kim SH; You YS; Kwon OW
Korean J Ophthalmol; 2015 Aug; 29(4):226-32. PubMed ID: 26240506
[TBL] [Abstract][Full Text] [Related]
57. Intravitreal injection of ranibizumab during cataract surgery in patients with diabetic macular edema.
Rauen PI; Ribeiro JA; Almeida FP; Scott IU; Messias A; Jorge R
Retina; 2012 Oct; 32(9):1799-803. PubMed ID: 22495327
[TBL] [Abstract][Full Text] [Related]
58. Intravitreal aflibercept for ranibizumab-resistant exudative age-related macular degeneration with choroidal vascular hyperpermeability.
Nomura Y; Yanagi Y
Jpn J Ophthalmol; 2015 Jul; 59(4):261-5. PubMed ID: 25983109
[TBL] [Abstract][Full Text] [Related]
59. Predictors of Outcome in Patients with Neovascular Age-Related Macular Degeneration Switched from Ranibizumab to 8-Weekly Aflibercept.
Chatziralli I; Nicholson L; Vrizidou E; Koutsiouki C; Menon D; Sergentanis TN; Citu MC; Hamilton R; Patel PJ; Hykin P; Sivaprasad S
Ophthalmology; 2016 Aug; 123(8):1762-1770. PubMed ID: 27289179
[TBL] [Abstract][Full Text] [Related]
60. Endophthalmitis Rates after Bilateral Same-Day Intravitreal Anti-Vascular Endothelial Growth Factor Injections.
Borkar DS; Obeid A; Su DC; Storey PP; Gao X; Regillo CD; Kaiser RS; Garg SJ; Hsu J;
Am J Ophthalmol; 2018 Oct; 194():1-6. PubMed ID: 29981738
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]